It's probably true that a company would be hard-pressed to do worse than Hospira (HSP)
has managed in recent years, but it doesn't automatically follow that
conditions will get quite a bit better. Hospira certainly could be a
better company in a few years' time, but "could" is a dangerous word
when it comes to investing. So although I am bullish on Hospira's
opportunities in biosimilars, I struggle to come up with a scenario
where this stock is priced to outperform.
Continue reading here:
The Street Is Much Too Optimistic About Hospira
No comments:
Post a Comment